VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $475.08, with a +1% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 0.33% for ...

Vertex Pharmaceuticals: "This company is doing the lord's work...I think it should be bought." CME Group: "It is one of the most consistent, great companies...It is a strong buy." T. Rowe Price ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive ...

The Uttarakhand Board of Secondary Education (UBSE) has released the provisional UTET 2024 answer key for both Paper I and II on its official website. Conducted on October 24, the exam consisted ...

Analyst Whitney Ijem from Canaccord Genuity maintained a Sell rating on Vertex Pharmaceuticals (VRTX – Research Report) and decreased the price target to $361.00 from $376.00. Whitney Ijem has ...